Table 2 Characteristics and data of high-risk patients in the initial treatment (IVIG+steroid)-responsive and initial treatment-resistant groups

Number

27

10

Age (months)

42 [11–80]

44 [9–86]

0.880

Male gender, n (%)

17 (63.0)

8 (80.0)

0.285

Illness day at diagnosis

4 [2–8]

3 [2–7]

0.220

Kobayashi score

6 [5–10]

6 [5–10]

0.216

TN-C, ng/mL

117.6 [35.0–324.8]

175.8 [80.4–380.9]

0.037

WBC, × 10³/μL

14.8 [6.6–33.2]

18.6 [6.9–36.8]

0.242

Neutrophils, %

83 [60–95]

88 [68–94]

0.191

Platelets, × 10⁴/mL

26.2 [13.1–59.4]

23.9 [13.5–36.6]

0.555

CRP, mg/dL

10.0 [2.5–24.0]

10.1 [5.2–21.7]

0.853

Albumin, g/dL

3.6 [2.7–4.1]

3.6 [2.8–4.4]

0.801

T-bilirubin, mg/dL

0.7 [0.3–5.5]

1.4 [0.5–4.6]

0.391

AST, IU/L

57 [20–787]

551 [25–2725]

0.013

ALT, IU/L

83 [8–937]

518 [9–1435]

0.067

Sodium, mEq/L

133 [127–137]

132 [128–135]

0.578